JPS639515B2 - - Google Patents
Info
- Publication number
- JPS639515B2 JPS639515B2 JP56095744A JP9574481A JPS639515B2 JP S639515 B2 JPS639515 B2 JP S639515B2 JP 56095744 A JP56095744 A JP 56095744A JP 9574481 A JP9574481 A JP 9574481A JP S639515 B2 JPS639515 B2 JP S639515B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorophenyl
- furylmethyl
- tetrahydro
- piperidyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 Tetrahydrofuran compound Chemical class 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 238000002844 melting Methods 0.000 description 27
- 230000008018 melting Effects 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OXPDQFOKSZYEMJ-UHFFFAOYSA-N 2-phenylpyrimidine Chemical compound C1=CC=CC=C1C1=NC=CC=N1 OXPDQFOKSZYEMJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BKKAHPUMRSDVDB-LDYMZIIASA-N (2r,4s)-2-(4-fluorophenyl)-4-(iodomethyl)oxolane Chemical compound C1=CC(F)=CC=C1[C@@H]1OC[C@@H](CI)C1 BKKAHPUMRSDVDB-LDYMZIIASA-N 0.000 description 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 2
- ZVAPQWJYBDLIGM-UHFFFAOYSA-N 2-(bromomethyl)-5-(4-fluorophenyl)oxolane Chemical compound C1=CC(F)=CC=C1C1OC(CBr)CC1 ZVAPQWJYBDLIGM-UHFFFAOYSA-N 0.000 description 2
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- JTCMRSIKVRPYPO-BCCWUKRQSA-N (Z)-but-2-enedioic acid 6-chloro-3-[1-[[(3S,5R)-5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@@H]1OC[C@H](CN2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)C1 JTCMRSIKVRPYPO-BCCWUKRQSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- BFEZPIYSZYJUQE-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-[1-[[5-(4-fluorophenyl)oxolan-2-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(F)=CC=C1C1OC(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 BFEZPIYSZYJUQE-WLHGVMLRSA-N 0.000 description 1
- JTCMRSIKVRPYPO-JHPSNSFNSA-N (z)-but-2-enedioic acid;6-chloro-3-[1-[[(3r,5r)-5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@@H]1OC[C@@H](CN2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)C1 JTCMRSIKVRPYPO-JHPSNSFNSA-N 0.000 description 1
- MNXJZPFHQXUUEF-BTJKTKAUSA-N (z)-but-2-enedioic acid;6-chloro-3-[1-[[5-(4-fluorophenyl)oxolan-2-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1C1OC(CN2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)CC1 MNXJZPFHQXUUEF-BTJKTKAUSA-N 0.000 description 1
- JTCMRSIKVRPYPO-BTJKTKAUSA-N (z)-but-2-enedioic acid;6-chloro-3-[1-[[5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1C1OCC(CN2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)C1 JTCMRSIKVRPYPO-BTJKTKAUSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 1
- DCOGKGVPMUKTTI-UHFFFAOYSA-N 1-(4-fluorophenyl)pent-4-en-1-ol Chemical compound C=CCCC(O)C1=CC=C(F)C=C1 DCOGKGVPMUKTTI-UHFFFAOYSA-N 0.000 description 1
- UPLAFFPDDJGWPE-UHFFFAOYSA-N 1-[1-[[5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-3-phenyl-1,3-diazinane-2,4-dione;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C1OCC(CN2CCC(CC2)N2C(N(C(=O)CC2)C=2C=CC=CC=2)=O)C1 UPLAFFPDDJGWPE-UHFFFAOYSA-N 0.000 description 1
- SNDBGOLQHNEUAZ-UHFFFAOYSA-N 3-[1-[[5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C1OCC(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)C1 SNDBGOLQHNEUAZ-UHFFFAOYSA-N 0.000 description 1
- WOZUWMCPRWUBQV-UHFFFAOYSA-N 3-[1-[[5-(4-fluorophenyl)oxolan-3-yl]methyl]piperidin-4-yl]-1h-benzimidazole-2-thione;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C1OCC(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=S)C1 WOZUWMCPRWUBQV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- BHPDHNQKHAJEBJ-KBXCAEBGSA-N [(3s,5r)-5-(4-fluorophenyl)oxolan-3-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@H]1C[C@H](C=2C=CC(F)=CC=2)OC1 BHPDHNQKHAJEBJ-KBXCAEBGSA-N 0.000 description 1
- ORZBAUJIMLQWCM-UHFFFAOYSA-N [5-(4-fluorophenyl)oxolan-3-yl]methanol Chemical compound C1C(CO)COC1C1=CC=C(F)C=C1 ORZBAUJIMLQWCM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003354 anti-apomorphinic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. âCOOH
- C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. âCOOH of carboxylic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
- C07C33/30—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Â -Â C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Â -Â C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
æ¬çºæã¯ãäžè¬åŒ
ã§è¡šããããæ°èŠãã€èªçºéåæå¶äœçšãæã¢ã
ã¢ã«ãã€ã³äœçšãã¬ã»ã«ãã³å¢åŒ·äœçšãªã©ã®è¬ç
äœçšãæããå粟ç¥è¬ãèè žç®¡éå調æŽãªã©ã®å»
è¬ãšããŠæçšãªããã©ããããã©ã³ååç©ããã³
ãããã®å»è¬çã«èš±å®¹ãããé žä»å å¡©ããã³ãã
ãã®è£œé æ³ã«é¢ããã äžèšåŒäžãArã¯ããšãã«ã眮æåºãšããŠãã
ã²ã³ãŸãã¯äœçŽã¢ã«ã³ãã·ãæããããšãã«ãã
Amã¯æ¬¡åŒã®åºããéžã°ããã¢ãã³æ®åºã瀺ãã
ã¢ã«ãã€ã³äœçšãã¬ã»ã«ãã³å¢åŒ·äœçšãªã©ã®è¬ç
äœçšãæããå粟ç¥è¬ãèè žç®¡éå調æŽãªã©ã®å»
è¬ãšããŠæçšãªããã©ããããã©ã³ååç©ããã³
ãããã®å»è¬çã«èš±å®¹ãããé žä»å å¡©ããã³ãã
ãã®è£œé æ³ã«é¢ããã äžèšåŒäžãArã¯ããšãã«ã眮æåºãšããŠãã
ã²ã³ãŸãã¯äœçŽã¢ã«ã³ãã·ãæããããšãã«ãã
Amã¯æ¬¡åŒã®åºããéžã°ããã¢ãã³æ®åºã瀺ãã
ãåŒã
ãåŒã
ãåŒã
ãåŒã
ïŒåŒäžãR1ã¯æ°ŽçŽ ãäœçŽã¢ã«ãã«ãããšãã«ã
眮æåºãšããŠäœçŽã¢ã«ãã«ãŸãã¯ïŒãïŒåã®ãã
ã²ã³ãæããããšãã«ããR2ã¯æ°ŽçŽ ãäœçŽã¢ã«
ãã«ããã¯æ°ŽçŽ ãããã²ã³ããã¯é žçŽ ååã
ç¡«é»ååã瀺ããïŒ äžèšã®å®çŸ©äžãäœçŽã¢ã«ãã«ãšã¯ã¡ãã«ããšã
ã«ããããã«ãã€ãœãããã«ãããã«ãªã©ãäœçŽ
ã¢ã«ã³ãã·ãšã¯ã¡ããã·ããšããã·ããããã
ã·ãã€ãœããããã·ããããã·ãªã©ãããã²ã³ãš
ã¯ããçŽ ãå¡©çŽ ãèçŽ ãªã©ã§ããã ããã©ããããã©ã³äžã®åºArãšCH2âAmã¯ä»»
æã®äœçœ®ã®çµåãããšãããã æ¬çºæã¯ååšããçš®ã ã®ç«äœç°æ§äœã®å šãŠãå
å«ãããã®ã§ããããããã®ç°æ§äœã¯ååãšã
ãŠããããã¯ïŒçµã®å åŠç°æ§äœãå«ããã©ã³ã¹ãŸ
ãã¯ã·ã¹äœãšããŠãè¥ããã¯ïŒçš®ã®ãžã¢ã¹ãã¬ãª
ããŒã®æ··åç©ãšããŠæ¬çºæãæ§æããããŸãç°æ§
äœã®æ··åç©ã¯åžžæ³ã«ããããããå åŠæŽ»æ§äœãšã
ãŠåé¢ããããšãã§ããç«äœéžæçã«åæããã
ãšãã§ããããŸãæ¬çºæã¯ãäºå€ç°æ§äœãååšã
ãå Žåã«ã¯ãããããå¿è«å å«ããã äžè¬åŒïŒïŒã®ååç©ã¯ãäžè¬åŒ ïŒåŒäžãArã¯åèšãšå矩ã§ãããã¯ããã²ã³
ïŒå¡©çŽ ãèçŽ ããšãŠçŽ ïŒãææ©ã¹ã«ããã«ãªãã·
ïŒãã·ã«ãªãã·ãã¡ã·ã«ãªãã·ãªã©ïŒã瀺ããïŒ ã§è¡šããããååç©ãšäžè¬åŒ âAm ïŒïŒ ïŒåŒäžãAmã¯åèšãšå矩ã§ãããïŒ ã§è¡šããããååç©ãšãåå¿ãããããšã«ãã補
é ãããã ãã®åå¿ã¯éåžžãã¡ã¿ããŒã«ããšã¿ããŒã«ãã€
ãœãããããŒã«ããã³ãŒã³ããã«ãšã³ããã·ã¬
ã³ããžã¡ãã«ãã«ã ã¢ãããã¯ãããã«ã ããžã¯
ãã«ãšã¿ã³ãã¢ã»ãã³ãã¡ãã«ãšãã«ã±ãã³ããž
ã¡ãã«ã¹ã«ãããµã€ããªã©ã®æº¶åªäžã§å®€æž©ãã
140âã奜ãŸããã¯50ã110âã§ãçé žã«ãªãŠã ã
çé žãããªãŠã ãããªãšãã«ã¢ãã³çã®ç¬¬äžçŽã¢
ãã³ãªã©ã®è±é žå€ã®ååšäžã«ïŒæéãã48æéã
奜ãŸããã¯ïŒæéãã18æéåå¿ãããŠåŸãã
ããããšãŠçŽ 以å€ã®å Žåãåå¿ã¯ãšãŠåã«ãªãŠ
ã ããšãŠåãããªãŠã ãªã©ã®è§Šåªã«ãã€ãŠä¿é²ã
ããããšãã§ããã äžè¬åŒïŒïŒã«ãããŠãAmãåŒ ïŒåŒäžããã¯åèšãšå矩ã§ãããïŒ ã®ã¢ãã³æ®åºã§ããå Žåã«ã¯ãäžèšã®æ¹æ³ã«ãã€
ãŠã補é ããããšãã§ãããããªãã¡ãäžè¬åŒ ïŒArãã¯åèšãšå矩ã§ãããïŒ ãã·ã¢ã³é žã¢ã«ã«ãªéå±ïŒã·ã¢ã³é žã«ãªãŠã ãã·
ã¢ã³é žãããªãŠã ãªã©ïŒãšãšã¿ããŒã«ãã€ãœãã
ãããŒã«ããã¿ããŒã«ãªã©ã®äœçŽã¢ã«ã³ãŒã«æº¶åª
äžã§å®€æž©ããéæµæž©åºŠã§åå¿ãããããšã«ãã
ãïŒã§ããååç©ãããŸãæ°Žé žåã¢ã«ã«ãªéå±
ïŒã«ã»ã€ãœãŒããã«ã»ã€ã«ãªãªã©ïŒã®ååšäžäºç¡«
åççŽ ãšäžèšäœçŽã¢ã«ã³ãŒã«æº¶åªäžã§å®€æž©ããé
æµæž©åºŠã§ç°åãããããšã«ãããã§ããåå
ç©ãåŸãããšãã§ãããäžè¬åŒïŒïŒã®ååç©ã¯
ç¹å ¬æ47â7267å·ã«é瀺ãããæ¹æ³ãæºçšããŠäž
èšã®åå¿åŒã«åŸã€ãŠè£œé ããããšãã§ããã äžè¬åŒïŒïŒã®ååç©ã¯é žä»å å¡©ã圢æããã
ããšãã§ãããããå»è¬çã«èš±å®¹ãããé žä»å å¡©
ã¯ä»£è¡šçã«ã¯ãå¡©é žãç¡«é žãçé žãã¡ã¿ã³ã¹ã«ã
ã³é žããã¬ã€ã³é žãã·ãŠãŠé žãã³ãã¯é žããããŒ
ã«é žãé ¢é žãä¹³é žãã¯ãšã³é žã«ãã圢æãããå¡©
ã§ããã æ¬çºæã®ååç©ã®è¬çäœçšã®äžã€ãšããŠã¢ãã¢
ã«ãã€ã³ã«å¯Ÿããäœçšã®å®éšäŸã次ã«ç€ºãã å®éšæ¹æ³ïŒïŒddç³»éæ§ããŠã¹ãäžçŸ€ïŒå¹ïŒïŒ
矀ïŒãšããŠçšããè©Šéšååç©30mgïŒKgãè ¹è å æ
äžããã30ååŸã¢ãã¢ã«ãã€ã³å¡©é žå¡©0.5mgïŒKg
ãç®äžæäžãçŽã¡ã«26Ã42Ã20é«ãïŒcmïŒã®éæ
ãã©ã¹ããã¯ã±ãŒãžå ã«çŸ€å± ãããã³ãã³ãã¹ç€Ÿ
補ã®ãªãŒãã¡ãã¯ã¹ã§10åã20åã30åã®åç©ã®
éåéã枬å®ããå¯Ÿç §çŸ€ãšã®éã§æææ§ãæ€èšã
ãã å®éšæ¹æ³ïŒïŒddç³»éæ§ããŠã¹ãäžçŸ€ïŒå¹ãšã
ãŠçšãããè©Šéšååç©çµå£æäž60ååŸã«ã¢ãã¢ã«
ãã€ã³å¡©é žå¡©0.5mgïŒKgãç®äžæäžããçŽåŸãã
20åéã®éåéãã¢ãã¡ãã¯ã¹ãçšããŠããã¹
ããè©Šéšååç©ã®ãããã«0.5ïŒ ã¡ãã«ã»ã«ããŒ
ãºæ¶²ãæäžããå¯Ÿç §çŸ€ã®éåéã«å¯Ÿãã50ïŒ æå¶
éãED50å€ãæ±ããã
眮æåºãšããŠäœçŽã¢ã«ãã«ãŸãã¯ïŒãïŒåã®ãã
ã²ã³ãæããããšãã«ããR2ã¯æ°ŽçŽ ãäœçŽã¢ã«
ãã«ããã¯æ°ŽçŽ ãããã²ã³ããã¯é žçŽ ååã
ç¡«é»ååã瀺ããïŒ äžèšã®å®çŸ©äžãäœçŽã¢ã«ãã«ãšã¯ã¡ãã«ããšã
ã«ããããã«ãã€ãœãããã«ãããã«ãªã©ãäœçŽ
ã¢ã«ã³ãã·ãšã¯ã¡ããã·ããšããã·ããããã
ã·ãã€ãœããããã·ããããã·ãªã©ãããã²ã³ãš
ã¯ããçŽ ãå¡©çŽ ãèçŽ ãªã©ã§ããã ããã©ããããã©ã³äžã®åºArãšCH2âAmã¯ä»»
æã®äœçœ®ã®çµåãããšãããã æ¬çºæã¯ååšããçš®ã ã®ç«äœç°æ§äœã®å šãŠãå
å«ãããã®ã§ããããããã®ç°æ§äœã¯ååãšã
ãŠããããã¯ïŒçµã®å åŠç°æ§äœãå«ããã©ã³ã¹ãŸ
ãã¯ã·ã¹äœãšããŠãè¥ããã¯ïŒçš®ã®ãžã¢ã¹ãã¬ãª
ããŒã®æ··åç©ãšããŠæ¬çºæãæ§æããããŸãç°æ§
äœã®æ··åç©ã¯åžžæ³ã«ããããããå åŠæŽ»æ§äœãšã
ãŠåé¢ããããšãã§ããç«äœéžæçã«åæããã
ãšãã§ããããŸãæ¬çºæã¯ãäºå€ç°æ§äœãååšã
ãå Žåã«ã¯ãããããå¿è«å å«ããã äžè¬åŒïŒïŒã®ååç©ã¯ãäžè¬åŒ ïŒåŒäžãArã¯åèšãšå矩ã§ãããã¯ããã²ã³
ïŒå¡©çŽ ãèçŽ ããšãŠçŽ ïŒãææ©ã¹ã«ããã«ãªãã·
ïŒãã·ã«ãªãã·ãã¡ã·ã«ãªãã·ãªã©ïŒã瀺ããïŒ ã§è¡šããããååç©ãšäžè¬åŒ âAm ïŒïŒ ïŒåŒäžãAmã¯åèšãšå矩ã§ãããïŒ ã§è¡šããããååç©ãšãåå¿ãããããšã«ãã補
é ãããã ãã®åå¿ã¯éåžžãã¡ã¿ããŒã«ããšã¿ããŒã«ãã€
ãœãããããŒã«ããã³ãŒã³ããã«ãšã³ããã·ã¬
ã³ããžã¡ãã«ãã«ã ã¢ãããã¯ãããã«ã ããžã¯
ãã«ãšã¿ã³ãã¢ã»ãã³ãã¡ãã«ãšãã«ã±ãã³ããž
ã¡ãã«ã¹ã«ãããµã€ããªã©ã®æº¶åªäžã§å®€æž©ãã
140âã奜ãŸããã¯50ã110âã§ãçé žã«ãªãŠã ã
çé žãããªãŠã ãããªãšãã«ã¢ãã³çã®ç¬¬äžçŽã¢
ãã³ãªã©ã®è±é žå€ã®ååšäžã«ïŒæéãã48æéã
奜ãŸããã¯ïŒæéãã18æéåå¿ãããŠåŸãã
ããããšãŠçŽ 以å€ã®å Žåãåå¿ã¯ãšãŠåã«ãªãŠ
ã ããšãŠåãããªãŠã ãªã©ã®è§Šåªã«ãã€ãŠä¿é²ã
ããããšãã§ããã äžè¬åŒïŒïŒã«ãããŠãAmãåŒ ïŒåŒäžããã¯åèšãšå矩ã§ãããïŒ ã®ã¢ãã³æ®åºã§ããå Žåã«ã¯ãäžèšã®æ¹æ³ã«ãã€
ãŠã補é ããããšãã§ãããããªãã¡ãäžè¬åŒ ïŒArãã¯åèšãšå矩ã§ãããïŒ ãã·ã¢ã³é žã¢ã«ã«ãªéå±ïŒã·ã¢ã³é žã«ãªãŠã ãã·
ã¢ã³é žãããªãŠã ãªã©ïŒãšãšã¿ããŒã«ãã€ãœãã
ãããŒã«ããã¿ããŒã«ãªã©ã®äœçŽã¢ã«ã³ãŒã«æº¶åª
äžã§å®€æž©ããéæµæž©åºŠã§åå¿ãããããšã«ãã
ãïŒã§ããååç©ãããŸãæ°Žé žåã¢ã«ã«ãªéå±
ïŒã«ã»ã€ãœãŒããã«ã»ã€ã«ãªãªã©ïŒã®ååšäžäºç¡«
åççŽ ãšäžèšäœçŽã¢ã«ã³ãŒã«æº¶åªäžã§å®€æž©ããé
æµæž©åºŠã§ç°åãããããšã«ãããã§ããåå
ç©ãåŸãããšãã§ãããäžè¬åŒïŒïŒã®ååç©ã¯
ç¹å ¬æ47â7267å·ã«é瀺ãããæ¹æ³ãæºçšããŠäž
èšã®åå¿åŒã«åŸã€ãŠè£œé ããããšãã§ããã äžè¬åŒïŒïŒã®ååç©ã¯é žä»å å¡©ã圢æããã
ããšãã§ãããããå»è¬çã«èš±å®¹ãããé žä»å å¡©
ã¯ä»£è¡šçã«ã¯ãå¡©é žãç¡«é žãçé žãã¡ã¿ã³ã¹ã«ã
ã³é žããã¬ã€ã³é žãã·ãŠãŠé žãã³ãã¯é žããããŒ
ã«é žãé ¢é žãä¹³é žãã¯ãšã³é žã«ãã圢æãããå¡©
ã§ããã æ¬çºæã®ååç©ã®è¬çäœçšã®äžã€ãšããŠã¢ãã¢
ã«ãã€ã³ã«å¯Ÿããäœçšã®å®éšäŸã次ã«ç€ºãã å®éšæ¹æ³ïŒïŒddç³»éæ§ããŠã¹ãäžçŸ€ïŒå¹ïŒïŒ
矀ïŒãšããŠçšããè©Šéšååç©30mgïŒKgãè ¹è å æ
äžããã30ååŸã¢ãã¢ã«ãã€ã³å¡©é žå¡©0.5mgïŒKg
ãç®äžæäžãçŽã¡ã«26Ã42Ã20é«ãïŒcmïŒã®éæ
ãã©ã¹ããã¯ã±ãŒãžå ã«çŸ€å± ãããã³ãã³ãã¹ç€Ÿ
補ã®ãªãŒãã¡ãã¯ã¹ã§10åã20åã30åã®åç©ã®
éåéã枬å®ããå¯Ÿç §çŸ€ãšã®éã§æææ§ãæ€èšã
ãã å®éšæ¹æ³ïŒïŒddç³»éæ§ããŠã¹ãäžçŸ€ïŒå¹ãšã
ãŠçšãããè©Šéšååç©çµå£æäž60ååŸã«ã¢ãã¢ã«
ãã€ã³å¡©é žå¡©0.5mgïŒKgãç®äžæäžããçŽåŸãã
20åéã®éåéãã¢ãã¡ãã¯ã¹ãçšããŠããã¹
ããè©Šéšååç©ã®ãããã«0.5ïŒ ã¡ãã«ã»ã«ããŒ
ãºæ¶²ãæäžããå¯Ÿç §çŸ€ã®éåéã«å¯Ÿãã50ïŒ æå¶
éãED50å€ãæ±ããã
ãè¡šã
ãè¡šã
è©Šéšååç©
ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâããªã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒ
âããšãã«ããªããžã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒ
âãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšã
ã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâ
ãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãª
ã³âïŒâãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãã
ãšãã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâ
ïŒâãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãã
ãŸãªã³âïŒâãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒ
âãªã³ã»ãã¬ã€ã³é žå¡© ãããã®æŽ»æ§ååç©ãå»è¬ãšããŠçšããå Žåã
ããèªäœãããã¯é©å®ã®è¬åŠçã«èš±å®¹ãããæ
äœã賊圢å€ãåžéå€ãšæ··åããç²æ«ãé¡ç²ãé
å€ãã«ãã»ã«å€ã泚å°å€ãªã©ã®åœ¢æ ã§çµå£çãŸã
ã¯éçµå£çã«æäžã§ãããæäžéã¯ïŒæ¥ãäœéKg
ããã0.005ã100mgã§ããã0.01ã50mgã奜ãŸã
ãããããã®æäžéã¯æ£è ã®ç ç¶ãäœéã幎霢ã
ããã¯æäžçµè·¯ã«ãã調æŽãããã 次ã«æ¬çºæã®åèäŸãšå®æœäŸãæããŠå ·äœçã«
説æããã åèäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒãããã
ã·ã¡ãã«ïŒããã©ããããã©ã³21ïœãããªãžã³
170mlã«æº¶è§£ããïŒâ以äžã§ãã·ã«ã¯ãã©ã€ã
24.4ïœãæ¹æäžå ãããããã«ïŒâã§ïŒæéã宀
æž©ã§ïŒæéæ¹æãããããªãžã³ã宀枩ã§æžå§çå»
åŸãæ®æ»ã«æ°Žãå ããŠé ¢é žãšãã«ã§æœåºãããæ
æ©å±€ãåžå¡©é žã§ïŒåãæ°Žã§ïŒåæŽã€ãã®ã¡ç¡«é žã
ã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæžå§çå»åŸæ®æ»ã«
ïœâãããµã³ãšã€ãœãããã«ãšãŒãã«ãå ãããš
èç¹46ã56âã®ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒ
âïŒãã·ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³
32.7ïœãåŸãããã ãã®ãã·ã«äœãã€ãœãããã«ãšãŒãã«ããåçµ
æ¶ãããè¿ããšãèç¹75ã76.5âã®ç¡è²éç¶æ¶ã®
ã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒãã·
ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³ãåŸãã
ãããŸãã¢ã«ã³ãŒã«ããåçµæ¶ãããšãèç¹55ã
57âã®ç¡è²éç¶æ¶ã®ãã©ã³ã¹ç°æ§äœãåŸãããã åèäŸ ïŒ ãã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâ
ïŒãã·ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³9.2
ïœããšãŠåãããªãŠã 12.6ïœãã¢ã»ãã³130mlã®
æ··åç©ãïŒæéå ç±éæµåŸã溶åªãæžå§çå»ã
ããæ®æ»ããšãŒãã«ã§æœåºããææ©å±€ãæ°ŽæŽãã
ç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãçå»ãã
ãšãå®éçã«ç¡è²æ²¹ç¶ç©ã®ãã©ã³ã¹âïŒâïŒïŒâ
ãã«ãªãããšãã«ïŒâïŒâïŒãšãŠãã¡ãã«ïŒããã©
ããããã©ã³ãåŸããããn27 D1.5675 åèäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâãã³ãããŒ
ã«7.4ïœãâããã¢ãµã¯ã·ã€ãã8.0ïœãã¯ãã
ãã«ã 100mlã宀枩ã§ïŒæéæ¹æãããåå¿æ¶²ã
æ°ŽæŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæž
å§çå»ããæ®æ»ãã·ãªã«ã²ã«ã¯ãããïŒã¯ããã
ã«ã ïŒã§ç²Ÿè£œãããšãç¡è²æ²¹ç¶ç©ã®ïŒâïŒïŒâã
ã«ãªãããšãã«ïŒâïŒâïŒããã¢ã¡ãã«ïŒããã©ã
ãããã©ã³9.8ïœãåŸããããD27 D1.5218 å®æœäŸ ïŒ ãã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâ
ïŒãšãŠãã¡ãã«ïŒããã©ããããã©ã³5.0ïœãïŒâ
ïŒïŒâãããªãžã«ïŒãã³ãºã€ãããŸãªã³âïŒâãª
ã³4.2ïœãçé žã«ãªãŠã 2.5ïœããžã¡ãã«ãã«ã ã¢
ãã80mlã®æ··åç©ã60ã70âã«42æéå ç±æ¹æã
ããåå¿æ¶²ãæ°Žäžã«æ³šãé ¢é žãšãã«ã§æœåºããã
ææ©å±€ãïŒåæ°ŽæŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ã
ãã溶åªãæžå§çå»åŸãã€ãœãããã«ãšãŒãã«ã
å ããŠçµæ¶ãæ¿Ÿåããã¢ã«ã³ãŒã«ããåçµæ¶ãã
ãšãèç¹154ã155âã®ç¡è²éç¶æ¶ãšããŠãïŒâ
ãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâ
ããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³5.1ïœãåŸ
ããããå¡©é žå¡©ã®èç¹239âïŒåè§£ïŒ å®æœäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒããã¢ã¡
ãã«ïŒããã©ããããã©ã³2.59ïœãïŒâïŒïŒâã
ããªãžã«ïŒãã³ãºã€ãããŸãªã³âïŒâãªã³2.17
ïœããšãŠåãããªãŠã 1.5ïœãçé žã«ãªãŠã 1.38
ïœããžã¡ãã«ãã«ã ã¢ãã30mlã®æ··åç©ã50ã60
âã«ïŒæéå ç±æ¹æãããåå¿æ¶²ãæ°Žäžã«æ³šãã¯
ãããã«ã ã§æœåºãããææ©å±€ãïŒåæ°ŽæŽãç¡«é ž
ãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæžå§çå»åŸãã·
ãªã«ã²ã«ã¯ãããïŒã¯ãããã«ã ïŒã«ä»ããŠåŸã
ããç¡è²æ²¹ç¶ç©ãã¢ã«ã³ãŒã«ã«ãšããããããŒã«
é žãå ãããæåºããçµæ¶ãã¢ã«ã³ãŒã«ããåçµ
æ¶ãããšãèç¹200ã201âã®ç¡è²éç¶æ¶ãšããŠã
ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©
ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãžã«ã
ãã³ãºã€ãããŸãªã³âïŒâãªã³ã»ãããŒã«é žå¡©ã
åŸãããã å®æœäŸ ïŒ ïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ïŒâïŒâïŒïŒâã¢ããã¢ã
ãªãïŒããã©ãžã³13.7ïœãäºç¡«åççŽ 18ïœãã«ã»
ã€ã«ãª4.2ïœãæ¹æäž3.5æéå ç±éæµãããå·
åŸãåå¿æ¶²ã«ã¢ã«ã³ãŒã«200mlãæ°Ž126mlãæ¿å¡©é ž
32mlãå ã20åéå ç±éæµãããæžå§äžã«æº¶åªã
çå»ããæ®æ»ã«ã¢ã³ã¢ãã¢æ°Žãå ããŠã¢ã«ã«ãªæ§
ã«ããé ¢é žãšãã«ã§æœåºãããæœåºæ¶²ãæ°ŽæŽãã
ç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãçå»åŸãæ®
æ»ãã·ãªã«ã²ã«ã¯ãããïŒã¯ãããã«ã ïŒã«ä»ã
ãŠåŸãããæ²¹ç¶ç©ã«ã¢ã«ã³ãŒã«æ§å¡©é žãå ããã
æåºããçµæ¶ãæ¿Ÿåããã¡ã¿ããŒã«âã€ãœããã
ã«ãšãŒã«ããåçµæ¶ãããšãèç¹269ã270âïŒå
解ïŒã®ç¡è²éç¶æ¶ãšããŠãïŒâãïŒâãïŒâïŒïŒâ
ãã«ãªãããšãã«ïŒâããã©ãããâïŒâããªã«
ã¡ãã«ãâïŒâãããªãžãããã³ãºã€ãããŸãªã³
âïŒâããªã³å¡©é žå¡©ãåŸãããã äžèšå®æœäŸãšåæ§ã«ããŠããšãã°æ¬¡ã®ååç©ã
補é ãããã âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ããã³ãºã€ãããŸãªã³âïŒâãªã³ãå¡©é žå¡©ã®
èç¹260âïŒåè§£ïŒ âïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâã
ããªãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³ãå¡©
é žå¡©ã®èç¹276âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹217âïŒåè§£ïŒ âïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâã
ããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³
âïŒâãªã³ãèç¹207.5ã208.5âããã¬ã€ã³é ž
å¡©ã®èç¹207âïŒåè§£ïŒ âïŒâãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãããš
ãã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâïŒ
âãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸ
ãªã³âïŒâãªã³ããã¬ã€ã³é žå¡©ã®èç¹208.5ã
209âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ããªã³ã1/2ãã¬ã€ã³é žå¡©ã®èç¹211âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹188ã190âïŒåè§£ïŒ âïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ãâïŒâïŒïŒâã¯ããã
ãšãã«ïŒâïŒâããããã·ãããªãžã³ãå¡©é žå¡©
ã®èç¹176ã178â âïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ãâïŒâã«ã«ãã¢ã€ã«
âïŒâãããªãžããããªãžã³ãïŒå¡©é žå¡©ã»ïŒæ°Ž
åç©ã®èç¹246âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœããªã
ãžã³ããããŒã«é žå¡©ã®èç¹127â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâã¡ãã«âïŒïŒïŒâãž
ãªããœããªããžã³ãå¡©é žå¡©ã®èç¹217âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ãå¡©é žå¡©ã®èç¹247âïŒå
è§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ããããŒã«é žå¡©ã»1/2æ°Žå
ç©ã®èç¹193ã196â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâã¡ãã«âïŒïŒïŒâãž
ãªããœâïŒâããšãã«ããªããžã³ãèç¹164â âïŒâãïŒâïŒïŒâããšãã«âããã©ãããâïŒâ
ããªã«ã¡ãã«ïŒâïŒâãããªãžã«ãâïŒâã¯ãã
âãã³ãºã€ãããŸãªã³âïŒâãªã³ããã¬ã€ã³é ž
å¡©ã®èç¹217ã218âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâã¯ããããšãã«ïŒâããã©
ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãžã«ã
âïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâãª
ã³ãèç¹172ã173â âïŒâãïŒâãïŒâïŒïŒâã¡ããã·ããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹233ã235âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâã¡ããã·ããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ãå¡©é žå¡©ã»1/2æ°Žåç©ã®è
ç¹219âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹200ã201âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒâã¯ããããšã
ã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãèç¹172ã
175â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒâã¯ããããšã
ã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãä¿®é žå¡©ã®
èç¹93âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïœâããªã«ïŒâïŒïŒ
ïŒâãžãªããœããªããžã³ãèç¹178ã181â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒïŒïŒâãžã¯ããã
ãšãã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãå¡©é ž
å¡©ã®èç¹304âïŒå解ïŒ
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâããªã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒ
âããšãã«ããªããžã³å¡©é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒ
âãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšã
ã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâ
ãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãª
ã³âïŒâãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãã
ãšãã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâ
ïŒâãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãã
ãŸãªã³âïŒâãªã³ã»ãã¬ã€ã³é žå¡© ïŒ ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâã
ãã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒ
âãªã³ã»ãã¬ã€ã³é žå¡© ãããã®æŽ»æ§ååç©ãå»è¬ãšããŠçšããå Žåã
ããèªäœãããã¯é©å®ã®è¬åŠçã«èš±å®¹ãããæ
äœã賊圢å€ãåžéå€ãšæ··åããç²æ«ãé¡ç²ãé
å€ãã«ãã»ã«å€ã泚å°å€ãªã©ã®åœ¢æ ã§çµå£çãŸã
ã¯éçµå£çã«æäžã§ãããæäžéã¯ïŒæ¥ãäœéKg
ããã0.005ã100mgã§ããã0.01ã50mgã奜ãŸã
ãããããã®æäžéã¯æ£è ã®ç ç¶ãäœéã幎霢ã
ããã¯æäžçµè·¯ã«ãã調æŽãããã 次ã«æ¬çºæã®åèäŸãšå®æœäŸãæããŠå ·äœçã«
説æããã åèäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒãããã
ã·ã¡ãã«ïŒããã©ããããã©ã³21ïœãããªãžã³
170mlã«æº¶è§£ããïŒâ以äžã§ãã·ã«ã¯ãã©ã€ã
24.4ïœãæ¹æäžå ãããããã«ïŒâã§ïŒæéã宀
æž©ã§ïŒæéæ¹æãããããªãžã³ã宀枩ã§æžå§çå»
åŸãæ®æ»ã«æ°Žãå ããŠé ¢é žãšãã«ã§æœåºãããæ
æ©å±€ãåžå¡©é žã§ïŒåãæ°Žã§ïŒåæŽã€ãã®ã¡ç¡«é žã
ã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæžå§çå»åŸæ®æ»ã«
ïœâãããµã³ãšã€ãœãããã«ãšãŒãã«ãå ãããš
èç¹46ã56âã®ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒ
âïŒãã·ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³
32.7ïœãåŸãããã ãã®ãã·ã«äœãã€ãœãããã«ãšãŒãã«ããåçµ
æ¶ãããè¿ããšãèç¹75ã76.5âã®ç¡è²éç¶æ¶ã®
ã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒãã·
ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³ãåŸãã
ãããŸãã¢ã«ã³ãŒã«ããåçµæ¶ãããšãèç¹55ã
57âã®ç¡è²éç¶æ¶ã®ãã©ã³ã¹ç°æ§äœãåŸãããã åèäŸ ïŒ ãã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâ
ïŒãã·ã«ãªãã·ã¡ãã«ïŒããã©ããããã©ã³9.2
ïœããšãŠåãããªãŠã 12.6ïœãã¢ã»ãã³130mlã®
æ··åç©ãïŒæéå ç±éæµåŸã溶åªãæžå§çå»ã
ããæ®æ»ããšãŒãã«ã§æœåºããææ©å±€ãæ°ŽæŽãã
ç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãçå»ãã
ãšãå®éçã«ç¡è²æ²¹ç¶ç©ã®ãã©ã³ã¹âïŒâïŒïŒâ
ãã«ãªãããšãã«ïŒâïŒâïŒãšãŠãã¡ãã«ïŒããã©
ããããã©ã³ãåŸããããn27 D1.5675 åèäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâãã³ãããŒ
ã«7.4ïœãâããã¢ãµã¯ã·ã€ãã8.0ïœãã¯ãã
ãã«ã 100mlã宀枩ã§ïŒæéæ¹æãããåå¿æ¶²ã
æ°ŽæŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæž
å§çå»ããæ®æ»ãã·ãªã«ã²ã«ã¯ãããïŒã¯ããã
ã«ã ïŒã§ç²Ÿè£œãããšãç¡è²æ²¹ç¶ç©ã®ïŒâïŒïŒâã
ã«ãªãããšãã«ïŒâïŒâïŒããã¢ã¡ãã«ïŒããã©ã
ãããã©ã³9.8ïœãåŸããããD27 D1.5218 å®æœäŸ ïŒ ãã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâ
ïŒãšãŠãã¡ãã«ïŒããã©ããããã©ã³5.0ïœãïŒâ
ïŒïŒâãããªãžã«ïŒãã³ãºã€ãããŸãªã³âïŒâãª
ã³4.2ïœãçé žã«ãªãŠã 2.5ïœããžã¡ãã«ãã«ã ã¢
ãã80mlã®æ··åç©ã60ã70âã«42æéå ç±æ¹æã
ããåå¿æ¶²ãæ°Žäžã«æ³šãé ¢é žãšãã«ã§æœåºããã
ææ©å±€ãïŒåæ°ŽæŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ã
ãã溶åªãæžå§çå»åŸãã€ãœãããã«ãšãŒãã«ã
å ããŠçµæ¶ãæ¿Ÿåããã¢ã«ã³ãŒã«ããåçµæ¶ãã
ãšãèç¹154ã155âã®ç¡è²éç¶æ¶ãšããŠãïŒâ
ãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒâ
ããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããª
ãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³5.1ïœãåŸ
ããããå¡©é žå¡©ã®èç¹239âïŒåè§£ïŒ å®æœäŸ ïŒ ïŒâïŒïŒâãã«ãªãããšãã«ïŒâïŒâïŒããã¢ã¡
ãã«ïŒããã©ããããã©ã³2.59ïœãïŒâïŒïŒâã
ããªãžã«ïŒãã³ãºã€ãããŸãªã³âïŒâãªã³2.17
ïœããšãŠåãããªãŠã 1.5ïœãçé žã«ãªãŠã 1.38
ïœããžã¡ãã«ãã«ã ã¢ãã30mlã®æ··åç©ã50ã60
âã«ïŒæéå ç±æ¹æãããåå¿æ¶²ãæ°Žäžã«æ³šãã¯
ãããã«ã ã§æœåºãããææ©å±€ãïŒåæ°ŽæŽãç¡«é ž
ãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãæžå§çå»åŸãã·
ãªã«ã²ã«ã¯ãããïŒã¯ãããã«ã ïŒã«ä»ããŠåŸã
ããç¡è²æ²¹ç¶ç©ãã¢ã«ã³ãŒã«ã«ãšããããããŒã«
é žãå ãããæåºããçµæ¶ãã¢ã«ã³ãŒã«ããåçµ
æ¶ãããšãèç¹200ã201âã®ç¡è²éç¶æ¶ãšããŠã
ïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©
ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãžã«ã
ãã³ãºã€ãããŸãªã³âïŒâãªã³ã»ãããŒã«é žå¡©ã
åŸãããã å®æœäŸ ïŒ ïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ïŒâïŒâïŒïŒâã¢ããã¢ã
ãªãïŒããã©ãžã³13.7ïœãäºç¡«åççŽ 18ïœãã«ã»
ã€ã«ãª4.2ïœãæ¹æäž3.5æéå ç±éæµãããå·
åŸãåå¿æ¶²ã«ã¢ã«ã³ãŒã«200mlãæ°Ž126mlãæ¿å¡©é ž
32mlãå ã20åéå ç±éæµãããæžå§äžã«æº¶åªã
çå»ããæ®æ»ã«ã¢ã³ã¢ãã¢æ°Žãå ããŠã¢ã«ã«ãªæ§
ã«ããé ¢é žãšãã«ã§æœåºãããæœåºæ¶²ãæ°ŽæŽãã
ç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ããã溶åªãçå»åŸãæ®
æ»ãã·ãªã«ã²ã«ã¯ãããïŒã¯ãããã«ã ïŒã«ä»ã
ãŠåŸãããæ²¹ç¶ç©ã«ã¢ã«ã³ãŒã«æ§å¡©é žãå ããã
æåºããçµæ¶ãæ¿Ÿåããã¡ã¿ããŒã«âã€ãœããã
ã«ãšãŒã«ããåçµæ¶ãããšãèç¹269ã270âïŒå
解ïŒã®ç¡è²éç¶æ¶ãšããŠãïŒâãïŒâãïŒâïŒïŒâ
ãã«ãªãããšãã«ïŒâããã©ãããâïŒâããªã«
ã¡ãã«ãâïŒâãããªãžãããã³ãºã€ãããŸãªã³
âïŒâããªã³å¡©é žå¡©ãåŸãããã äžèšå®æœäŸãšåæ§ã«ããŠããšãã°æ¬¡ã®ååç©ã
補é ãããã âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ããã³ãºã€ãããŸãªã³âïŒâãªã³ãå¡©é žå¡©ã®
èç¹260âïŒåè§£ïŒ âïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâã
ããªãžã«ããã³ãºã€ãããŸãªã³âïŒâãªã³ãå¡©
é žå¡©ã®èç¹276âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹217âïŒåè§£ïŒ âïŒâãïŒâãã·ã¹âïŒâïŒïŒâãã«ãªãããšãã«ïŒ
âããã©ãããâïŒâããªã«ã¡ãã«ãâïŒâã
ããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³
âïŒâãªã³ãèç¹207.5ã208.5âããã¬ã€ã³é ž
å¡©ã®èç¹207âïŒåè§£ïŒ âïŒâãïŒâããã©ã³ã¹âïŒâïŒïŒâãã«ãªãããš
ãã«ïŒâããã©ãããâïŒâããªã«ã¡ãã«ãâïŒ
âãããªãžã«ãâïŒâã¯ããâãã³ãºã€ãããŸ
ãªã³âïŒâãªã³ããã¬ã€ã³é žå¡©ã®èç¹208.5ã
209âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ããªã³ã1/2ãã¬ã€ã³é žå¡©ã®èç¹211âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹188ã190âïŒåè§£ïŒ âïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ãâïŒâïŒïŒâã¯ããã
ãšãã«ïŒâïŒâããããã·ãããªãžã³ãå¡©é žå¡©
ã®èç¹176ã178â âïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâããã©ã
ããâïŒâããªã«ã¡ãã«ãâïŒâã«ã«ãã¢ã€ã«
âïŒâãããªãžããããªãžã³ãïŒå¡©é žå¡©ã»ïŒæ°Ž
åç©ã®èç¹246âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœããªã
ãžã³ããããŒã«é žå¡©ã®èç¹127â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâã¡ãã«âïŒïŒïŒâãž
ãªããœããªããžã³ãå¡©é žå¡©ã®èç¹217âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ãå¡©é žå¡©ã®èç¹247âïŒå
è§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ããããŒã«é žå¡©ã»1/2æ°Žå
ç©ã®èç¹193ã196â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâã¡ãã«âïŒïŒïŒâãž
ãªããœâïŒâããšãã«ããªããžã³ãèç¹164â âïŒâãïŒâïŒïŒâããšãã«âããã©ãããâïŒâ
ããªã«ã¡ãã«ïŒâïŒâãããªãžã«ãâïŒâã¯ãã
âãã³ãºã€ãããŸãªã³âïŒâãªã³ããã¬ã€ã³é ž
å¡©ã®èç¹217ã218âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâã¯ããããšãã«ïŒâããã©
ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãžã«ã
âïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâãª
ã³ãèç¹172ã173â âïŒâãïŒâãïŒâïŒïŒâã¡ããã·ããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹233ã235âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâã¡ããã·ããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒïŒïŒâãžãªããœâïŒâ
ããšãã«ããªããžã³ãå¡©é žå¡©ã»1/2æ°Žåç©ã®è
ç¹219âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâïŒâã¯ããâãã³ãºã€ãããŸãªã³âïŒâ
ãªã³ããã¬ã€ã³é žå¡©ã®èç¹200ã201âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒâã¯ããããšã
ã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãèç¹172ã
175â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒâã¯ããããšã
ã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãä¿®é žå¡©ã®
èç¹93âïŒåè§£ïŒ âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïœâããªã«ïŒâïŒïŒ
ïŒâãžãªããœããªããžã³ãèç¹178ã181â âïŒâãïŒâãïŒâïŒïŒâãã«ãªãããšãã«ïŒâãã
ã©ãããâïŒâããªã«ã¡ãã«ãâïŒâãããªãž
ã«ãâãããµãããâïŒâïŒïŒïŒïŒâãžã¯ããã
ãšãã«ïŒâïŒïŒïŒâãžãªããœããªããžã³ãå¡©é ž
å¡©ã®èç¹304âïŒå解ïŒ
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ã§è¡šããããããã©ããããã©ã³ååç©ãŸãã¯ã
ã®å¡©é¡ã ïŒåŒäžãArã¯ããšãã«ã眮æåºãšããŠããã²ã³
ãŸãã¯äœçŽã¢ã«ã³ãã·ãæããããšãã«ããAm
ã¯æ¬¡ã®åŒã®åºããéžã°ããã¢ãã³æ®åºã瀺ãã ãåŒã ãåŒã ãåŒã ãåŒã ããã§ãR1ã¯æ°ŽçŽ ãäœçŽã¢ã«ãã«ãããšãã«ã
眮æåºãšããŠäœçŽã¢ã«ãã«ãŸãã¯ïŒãïŒåã®ãã
ã²ã³ãæããããšãã«ããR2ã¯æ°ŽçŽ ãäœçŽã¢ã«
ãã«ããã¯æ°ŽçŽ ãããã²ã³ããã¯é žçŽ ååã
ç¡«é»ååã瀺ããïŒ
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56095744A JPS57212180A (en) | 1981-06-19 | 1981-06-19 | Tetrahydrofuran(thiophene) compound |
EP82105315A EP0068331B1 (en) | 1981-06-19 | 1982-06-17 | Tetrahydrofuran compounds and analogs thereof |
DE8282105315T DE3268521D1 (en) | 1981-06-19 | 1982-06-17 | Tetrahydrofuran compounds and analogs thereof |
US06/390,433 US4414216A (en) | 1981-06-19 | 1982-06-21 | Tetrahydrofuran compounds and analogs thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56095744A JPS57212180A (en) | 1981-06-19 | 1981-06-19 | Tetrahydrofuran(thiophene) compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57212180A JPS57212180A (en) | 1982-12-27 |
JPS639515B2 true JPS639515B2 (ja) | 1988-02-29 |
Family
ID=14145994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56095744A Granted JPS57212180A (en) | 1981-06-19 | 1981-06-19 | Tetrahydrofuran(thiophene) compound |
Country Status (4)
Country | Link |
---|---|
US (1) | US4414216A (ja) |
EP (1) | EP0068331B1 (ja) |
JP (1) | JPS57212180A (ja) |
DE (1) | DE3268521D1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK139684A (da) * | 1983-04-11 | 1984-10-12 | Janssen Pharmaceutica Nv | N-aryl-alpha-amino-carboxamider |
DE3731198A1 (de) * | 1987-02-07 | 1988-08-18 | Bayer Ag | 2-aminomethyltetrahydrofurane |
US4816585A (en) * | 1987-03-05 | 1989-03-28 | Olin Corporation | Tetraalkylpiperidinyl substituted uracil derivatives and their use as ultraviolet light stabilizers |
US4904714A (en) * | 1987-10-02 | 1990-02-27 | Olin Corporation | Synthetic resin composition and its method of use |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | ãšãŒã¶ã€æ ªåŒäŒç€Ÿ | ç°ç¶ã¢ããèªå°äœ |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
WO2002083673A1 (en) * | 2001-04-10 | 2002-10-24 | Ortho-Mcneil Pharmaceutical, Inc. | 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
JP2005521662A (ja) * | 2002-01-25 | 2005-07-21 | ãµã³ã¿ã©ã¹ ã€ã³ã³ãŒãã¬ã€ãã£ãã | ãããã³ãã³ãé»å®³å€ã®çµç²èéé |
CN100402529C (zh) * | 2002-09-09 | 2008-07-16 | 詹森è¯äžæéå ¬åž | çšäºæ²»çorl-1åäœä»å¯ŒçŸç ççŸåºç·åºå代ç1,3,8-äžæ°®æèº[4,5]çž-4-é ®è¡çç© |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2008067167A1 (en) * | 2006-11-28 | 2008-06-05 | Janssen Pharmaceutica N.V. | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
WO2008124209A1 (en) * | 2007-04-09 | 2008-10-16 | Janssen Pharmaceutica, N.V. | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3629267A (en) * | 1968-10-28 | 1971-12-21 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione |
US3826835A (en) * | 1971-01-08 | 1974-07-30 | Ciba Geigy Corp | 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics |
US4148796A (en) * | 1971-03-15 | 1979-04-10 | Sumitomo Chemical Company, Limited | γ-Piperidinobutyrophenones |
JPS5755714B2 (ja) * | 1972-03-18 | 1982-11-25 | ||
US4264613A (en) * | 1979-08-01 | 1981-04-28 | Science Union Et Cie, Societe Francaise De Recherche Medicale | Piperidylbenzimidazolinone compounds |
JPS6043064B2 (ja) * | 1979-11-28 | 1985-09-26 | ãŠã§ã«ãã¡ã€ãæ ªåŒäŒç€Ÿ | æ°èŠã€ãœãªããµãŸâã«èªå°äœ |
US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
-
1981
- 1981-06-19 JP JP56095744A patent/JPS57212180A/ja active Granted
-
1982
- 1982-06-17 DE DE8282105315T patent/DE3268521D1/de not_active Expired
- 1982-06-17 EP EP82105315A patent/EP0068331B1/en not_active Expired
- 1982-06-21 US US06/390,433 patent/US4414216A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0068331A1 (en) | 1983-01-05 |
US4414216A (en) | 1983-11-08 |
EP0068331B1 (en) | 1986-01-15 |
DE3268521D1 (en) | 1986-02-27 |
JPS57212180A (en) | 1982-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS639515B2 (ja) | ||
US4397853A (en) | Isoxazole derivatives | |
JP2656189B2 (ja) | ãã³ãŸã€ãœãã¢ãŸãŒã«ããã³ãã³ãŸã€ãœããµãŸãŒã«âïŒâã«ã«ãããµããããã®è£œæ³ããã³ãããããªãæ粟ç¥ç å€ | |
JPH1059961A (ja) | æãã¹ã¿ãã³æŽ»æ§ãæããæ°èŠãã³ãºã€ãããŸãŒã«èªå°äœ | |
US20040162324A1 (en) | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | |
HU196370B (en) | Process for producing piperidine derivatives and pharmaceutical compositions comprising such compounds | |
US6355642B1 (en) | Tetrahydrobenzindole compounds | |
SK283461B6 (sk) | Deriváty oxadiazolu a tiadiazolu, ich pouÅŸitie, spÃŽsob a medziprodukty na ich vÃœrobu a farmaceutické kompozÃcie na ich báze | |
NO146359B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater | |
BG110058A (bg) | ÐÑОпОпÑазПлПвО ÑПлО | |
US4021552A (en) | 10-[Ï-(BENZOYLPIPERIDINYL)ALKYL]PHENOTHIAZINES | |
US4654352A (en) | Method for treating diarrhea with benzothiophene derivatives | |
JPH04234386A (ja) | ã«ã«ãã¹ããªã«èªå°äœ | |
JPS6330911B2 (ja) | ||
NL8002071A (nl) | 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)- benzoee- zuurderivaten, werkwijze voor de bereiding daarvan, alsmede farmaceutische preparaten die deze bevatten. | |
EP0505465B1 (en) | 4-Heterocyclyl-piperidine derivatives, their preparation and their use as inhibitors of calcium overload in brain cells | |
US5240927A (en) | Benzo[β]thiophen-3-yl piperazines as antipsychotic agents | |
US4076821A (en) | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof | |
WO1992001686A1 (en) | 1,4-disubstituted piperazines | |
SU895291A3 (ru) | СпПÑПб пПлÑÑеМО пÑПОзвПЎМÑÑ 4-аЌОМП-2-пОпеÑÐžÐŽÐžÐœÐŸÑ ÐžÐœÐ°Ð·ÐŸÐ»ÐžÐœÐ° ОлО ÐžÑ ÑПлей Ñ ÑаÑЌаÑевÑОÑеÑкО пÑОеЌлОЌÑЌО кОÑлПÑаЌО | |
US4009275A (en) | Phenoxypropylamine derivatives | |
CZ2002499A3 (cs) | Derivát piperidinalkoholu, způsob jeho pÅÃpravy, jeho pouÄŸità a farmaceutickÃœ prostÅedek, kterÃœ ho obsahuje | |
JP3253096B2 (ja) | ã€ã³ããªã«ãããããŒã«ããã®è£œé æ³ããã³äœ¿çšæ³ã䞊ã³ã«è©²ååç©ãå«ã調åç© | |
CZ155994A3 (en) | Piperidines and piperazines | |
US4029786A (en) | Morpholine derivatives for treating depression |